Promacta Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation;. October 2024. Available at
See full prescribing information for PROMACTA. PROMACTA (eltrombopag) tablets, for oral use PROMACTA (eltrombopag) for oral suspension Initial U.S. Approval: 2024 WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY See full prescribing information for complete boxed warning.
Promacta (eltrombopag) Prescribing and Labeling Information . Content current as of: . Postmarket Drug Safety Information for Patients and Providers
On 26 August, 2024, eltrombopagmarketed as Promacta in the USA For the full US Prescribing Information for Promacta, including
PROMACTA at 25 platelet count required to initiate antiviral therapy. Do not exceed a daily - indication) were: HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROMACTA safely and effectively. See full prescribing information for PROMACTA.
See full prescribing information for PROMACTA. PROMACTA (eltrombopag) tablets, for oral use PROMACTA (eltrombopag) for oral suspension Initial U.S. Approval: 2024 . WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C . RISK OF HEPATOTOXICITY . See full prescribing information for complete boxed warning.
Eltrombopag (Promacta) prescribing information; Revised March 2024. GSK, Research Triangle Park, NC. 10. Romiplostim (Nplate) prescribing
(See Section 5.1 of the full Prescribing Information for additional information). Hepatotoxicity: Promacta can cause liver enzyme elevation
PRESCRIBING INFORMATION FOR DOSAGE GUIDELINES AND OTHER INFORMATION RELATED TO THIS MEDICATION BEFORE Promacta (eltrombopag) [package insert].
Comments
SHOULD BE:
Andy had literally simply RELAYED all the various information.